What's breaking now, across thousands of outlets.
Mark Cuban's Cost Plus Drugs says it can reduce manufacturing costs for custom rare disease drugs and n-of-1 gene therapies.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.
Over in the AI space, investors are also increasingly wary of the massive amounts of money being poured into data centers.
Schonfeld Strategic Advisors has more than tripled its London business development headcount since 2022, reflecting increased investment in portfolio manager recruitment, according to a report by…
As turbulence grows in many countries, it is tempting to ask if there is a global hegemon that can sort everything out fairly.
South African Finance Minister Enoch Godongwana is poised to unveil a fiscal anchor to entrench progress made in repairing the nation’s public finances as the Iran war puts those gains to the test.
This high-yielding pipeline stock could be on the verge of increased dividend growth in the years ahead.
